Zavante Therapeutics

Developing novel therapies to improve the outcomes of hospitalized patients

Zavante Therapeutics is a clinical late-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. The company's lead product candidate, ZTI-01, is a novel injectable antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains where current therapeutic choices are severely limited. Zavante's leadership team (including CEO Ted Schroeder and Chairman Cam Garner) was previously affiliated with Cadence Pharmaceuticals, which sold to Mallinckrodt in 2014.

Year of Investment

2016

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

San Diego, California